In the investing game, it’s not only about what you buy; it’s about when you buy it. One of the most common pieces of advice thrown around the Street, “buy low” is touted as a tried-and-true tactic.Sure, the strategy seems simple. Stock prices naturally fluctuate on the basis of several factors like earnings results and the macro environment, amongst others, with investors trying to time the market and determine when stocks have hit a bottom. In practice, however, executing on this strategy is no easy task.On top of this, given the volatility that has ruled the markets over the last few weeks, how are investors supposed to gauge when a name is flirting with a bottom? That’s where the Wall Street pros come in.These expert stock pickers have identified three compelling tickers whose current share prices land close to their 52-week lows. Noting that each is set to take back off on an upward trajectory, the analysts see an attractive entry point. Using TipRanks’ database, we found out that the analyst consensus has rated all three a Strong Buy, with major upside potential also on tap.Progenity (PROG)Offering clear and actionable genetic results, Progenity specializes in providing testing services. The company started trading on Nasdaq in June and saw its shares tumbling 44% since then. With shares changing hands for $8.11, several members of the Street recommend pulling the trigger before it heats up.Piper Sandler analyst Steven Mah points out that even against the backdrop of COVID-19, PROG managed to deliver with its Q2 2020 performance. “We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening,” the analyst noted. Expounding on this, Mah stated, “Progenity did not provide guidance, but June test volumes of ~28,000 were strong (Q1 2020 monthly average was ~26,000) which we believe showcases the durability of its reproductive tests and the success that Progenity has in co-marketing and attaching carrier screening to the more essential NIPT. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.”Additionally, health insurer Aetna is temporarily extending coverage of average-risk NIPT until year-end as a result of the pandemic, with the American College of Obstetricians and Gynecologists (ACOG) also expected to endorse average-risk in the future given its clinical utility, in Mah’s opinion.Reflecting another positive, the fourth generation NIPT (single-molecule counting assay) test was able to measure fetal fraction, a key milestone according to Mah, and will continue to be developed into 2021. As the technology could potentially be applied to DNA, RNA, epigenetic markers and proteins for additional clinical applications such as oncology, the analyst is looking forward to the completion of the preeclampsia verification in Q4 2020 and a possible 2H21 launch. “We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing,” the analyst added.If that wasn’t enough, PROG signed its first GI Precision Medicine partnership agreement with a top-20 Pharma company in August. The Oral Biotherapeutic Delivery System (OBDS), an ingestible drug and device combination designed to precisely deliver biologics systemically through a needle-free liquid jet injection into the submucosal tissues of the small intestine, is set to be utilized as part of the collaboration. Mah commented, “We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.”To sum it all up, Mah said, “We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.”To this end, Mah rates PROG an Overweight (i.e. Buy) along with a $17 price target. Should his thesis play out, a twelve-month gain of 105% could potentially be in the cards. (To watch Mah’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4, in fact, have been issued in the last three months. Therefore, the message is clear: PROG is a Strong Buy. Given the $13.33 average price target, shares could climb 60% higher in the next year. (See PROG stock analysis on TipRanks)Tactile Systems Technology (TCMD)Developing at-home therapy devices, Tactile Systems Technology wants to provide new treatments for lymphedema, which occurs when the lymphatic system is impaired, disrupting normal transport of fluid within the body, and chronic venous insufficiency. Down 52% year-to-date, its $32.67 share price lands close to its $29.47 52-week low. Thus, with business trends improving, the Street is pounding the table.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the company, with COVID-19 weighing on both volumes and sales. In the second half of March, volumes were down 50% compared to the first half of the month, and TCMD’s patient volumes in April and May remained challenged. That being said, trends started to improve at the end of May.“Going forward, given the vast majority of TCMD’s clinician customers practice in outpatient or office-based settings, we remain positive on TCMD’s ability to demonstrate better insulation against COVID impacts and likely experience a greater bounce-back relative to overall med-tech volume trends, with TCMD further benefitting from its expanding using of technology to remotely engage with clinicians and support patients,” Furlong explained.The analyst added, “Furthermore, recent trends among some providers to prescribe Flexitouch (an advanced intermittent pneumatic compression device to self-manage lymphedema and nonhealing venous leg ulcers) earlier along the therapy process, as a means to reduce in-person contact, could provide upside near term, as well as potentially transition to a longer-term tailwind.”On top of this, Furlong is also optimistic about new CEO Dan Reuvers and the reprioritization of the company’s investment and market development efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments toward its Flexitouch and Entre (a pneumatic compression device used to assist in the home management of chronic swelling and venous ulcers associated with lymphedema and chronic venous insufficiency) products.“Given significant under-penetration in the lymphedema/phlebolymphedema market targeted by Flexitouch alongside the large patient population with limited treatment options today targeted by the firm’s Head & Neck platform, we view the combination of education and clinical data as key to further developing and penetrating these markets… Going forward, we expect management to continue to compile a broad base of clinical data to support reimbursement and drive broad adoption,” Furlong commented.All of this prompted Furlong to keep a Buy rating and $62 price target on the stock. This target conveys her confidence in TCMD’s ability to soar 90% in the next year. (To watch Furlong’s track record, click here)In general, other analysts are on the same page. With 3 Buy ratings and 1 Hold, the word on the Street is that TCMD is a Strong Buy. The $62.33 average price target brings the upside potential to 91%. (See TCMD stock analysis on TipRanks)uniQure N.V. (QURE)Last but not least we have uniQure, which delivers curative gene therapies that could potentially transform the lives of patients. Even though shares have fallen 44% year-to-date to $40, not much higher than its 52-week low of $36.20, multiple analysts still have high hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after news broke of its collaboration and licensing agreement with CSL Behring for AMT-061, QURE’s gene therapy for Hemophilia B, he argues the “shareholder base turnover is likely now complete as investors and QURE shift focus to next-in-line AMT-130, its AAV5 gene therapy for Huntington’s Disease (HD).”Schwartz further added, “With the M&A premium now out of the stock, we see the QURE’s current level as an attractive buying opportunity for those investors interested in the company’s up and coming CNS gene therapies, internal manufacturing, and robust intellectual property and knowhow.”Looking more closely at the agreement with CSL Behring, QURE will be tasked with the completion of the pivotal Phase 3 HOPE-B trial as well as the manufacturing process validation and manufacturing supply of AMT-061.According to management, 26-week Factor IX (FIX) data from all 54 patients enrolled in the trial remains on track, and topline data from the pivotal trial is still slated to read out by YE20. It should be mentioned that in a Phase 2b dose-confirmation study, QURE reported 41% FIX activity out to one year. Additionally, Schwartz points out that with HOPE-B progressing as planned, QURE has continued its manufacturing process validation work ahead of the anticipated BLA/MAA submissions in the U.S. and EU in 2021.On top of this, as part of the deal, QURE is eligible to receive more than $2 billion including a $450 million upfront cash payment, $1.6 billion in regulatory and commercial milestones and double-digit royalties ranging up to the low-twenties percentage of net product sales.“With a strengthened cash position, QURE is well funded to rapidly advance CNS assets including AMT-130 (AAV5 gene therapy for Huntington’s Disease (HD)) and AMT-150 (AAV gene therapy for Spinocerebellar Ataxia Type 3/SCA3)…We continue to believe that as QURE’s CNS pipeline assets mature, the company could once again be an attractive partner to larger biopharma companies that have recently acquired many publicly traded gene therapy platforms with substantial manufacturing capabilities,” Schwartz noted.Everything that QURE has going for it convinced Schwartz to reiterate an Outperform (i.e. Buy) rating. Along with the call, he attached a $67 price target, suggesting 68% upside potential from current levels. (To watch Schwartz’s track record, click here)What does the rest of the Street have to say? 9 Buys and 3 Holds have been issued in the last three months, so the consensus rating is a Strong Buy. In addition, the $69.89 average price target indicates 75% upside potential. (See QURE stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Owner of all-electric Nissan Leaf frustrated by difficulty of getting new battery – CBC.ca
You might think that Nissan, the first car-maker to achieve widespread success with a zero-emissions electric vehicle, cares deeply about the environment. But Clayton Brander isn’t so sure.
Three years ago, the Powell River, B.C., resident chose to buy a used 2013 Nissan Leaf, motivated by a keen interest in sustainability.
“I love the car,” he said. “Honestly, in three years and 40,000 kilometres, I’ve replaced a set of tires and windshield wiper fluid. Nothing breaks down. It’s a fantastic little vehicle. I think electric vehicles are the way to go.”
But nowadays, instead of being able to drive the 120 km that 2013 Leafs could initially go on a full charge, Brander can’t get much more than 80 km. He has even become hesitant about turning on the heat or window defroster, since using those features require battery power and will reduce his driving range even further.
Brander always knew that batteries lose capacity over time, and he figured it wouldn’t be a problem getting a new one.
“The dealership where I bought the car said that in a few years, you can replace the battery for about $5,000,” said Brander.
But now, he can’t find one. He’s tried two nearby Nissan dealerships, three local repair shops and contacted Nissan Canada.
“Nissan hasn’t been helpful. I’ve sent probably six emails to them,” said Brander. “They keep telling me to go to the dealership. I called my local dealership and they sent emails to Nissan Canada. Six weeks later, neither of us has gotten a response.”
Both dealerships told him that a new battery — if he can find one — could cost him at least $15,000, which would be more than he paid for the vehicle in the first place.
WATCH | Brander’s struggle to replace his car’s battery:
His local dealership has encouraged him to solve the issue by simply purchasing a brand-new Nissan Leaf. The basic 2020 model costs $42,000 and can travel about 240 km on a full charge. That suggestion doesn’t seem very sustainable to Brander.
“It seems like these things are going to end up in the landfill,” he said. “It makes more sense for them financially, I imagine, to sell new cars than to service the old cars.”
U.S. class-action lawsuit
The Nissan Leaf has long been the world’s best-selling electric vehicle, surpassed for the first time in 2020 by Tesla’s Model S, according to Nissan and Tesla’s own figures.
Olivier Trescases, a professor at the University of Toronto’s Electric Vehicle Research Centre, said Nissan deserves credit for being a pioneer.
“They were one of the first to release a compelling electric vehicle with a reasonable range and most importantly, a low price point,” he said.
But he added that one of the design “compromises” Nissan initially made in order to keep production costs down was to not install an advanced cooling system for its batteries. “They were using a chemistry that was particularly temperature-sensitive, and they did not use expensive liquid cooling.”
That means the battery’s capacity is reduced more quickly. In 2012, Leaf owners in California and Arizona launched a class-action lawsuit claiming the car’s driving range was lower than advertised.
The company settled the suit and extended the battery capacity warranty to five years on models made from 2013 onward. Later, Nissan extended the warranty to eight years on models made after 2016.
As well, a battery replacement program for first-generation Leafs was launched in the U.S. A new one cost $5,499 US, plus labour, but the program was discontinued in early 2018.
Where’s the loyalty?
After an inquiry about Clayton Brander’s situation from CBC’s Go Public team, Nissan declined an interview but released a statement via email. It said Nissan Canada will conduct an inspection of Brander’s vehicle and is “hopeful to find a resolution.”
Contacted by phone, the head of corporate communications for Nissan Canada wouldn’t clarify if that means that they would find him a new battery, or at what price.
The statement also pointed out the environmental impact of the Leaf, saying owners around the world have driven 4.8 billion kilometres and helped to prevent “more than 2.4 billion kilograms of CO2 emissions.”
Trescases believes Nissan should show more loyalty to its first customers. “Some of these early adopters helped them to get the car out on the market, get some acceptance and go from there.”
Nissan Canada says more than 3,300 Canadians have purchased Leafs built prior to 2015.
Trescases said the challenge of replacing batteries in older electric cars shouldn’t discourage buyers of newer models, explaining the latest EV batteries are incredibly efficient.
“Today, companies are talking about million-mile batteries,” he said. “That’s a big buzzword, but let’s say they even get close to that — that means that the battery will actually outlive the car by a long stretch.”
Keeping car on the road
At just seven years old, Brander’s Leaf is newer than most cars on the road in Canada, where the average vehicle is 10 years old. (In B.C., the average is 11.)
He remains determined to hang on to the vehicle, ideally with a new battery. He’s happy that Nissan Canada finally got in touch with him after the inquiry from CBC News, but he’s puzzled why the company says the vehicle needs to be tested. He said he already paid $130 for a battery test at a local dealership.
“The fact that I don’t get enough driving range out of this one is all that’s needed to determine that I need a new battery,” he said.
He’d like to see Nissan show some loyalty to its most faithful fans, by helping keep the cars on the road for as long as possible.
“They got all the kudos for introducing the electric vehicles to the masses, so that looks really good,” he said.
“But they’re losing them now by not supporting these older models and just pushing new vehicle sales, instead of saying, ‘Look, we can still keep these out of the landfill.'”
WestJet pilots protest ‘outsourced’ flights to Swoop in Calgary – Global News
About 50 WestJet pilots protested outside the Calgary International Airport on Sunday to draw attention to what they call the “outsourcing” of WestJet flights to low-cost carrier Swoop.
Though both are owned by the same company — the WestJet Group — protesters said Swoop is flying WestJet’s routes, which means fewer hours for WestJet pilots.
“The biggest issue for us is routes that have been flown by WestJet Airlines over the last two decades are now being flown by Swoop,” said Capt. Dave Colquhoun, WestJet Master Executive Council chair.
“When Swoop was initially envisioned, we were told that wouldn’t happen. Now that it started to happen, especially out of Toronto, we’re concerned about that and we want to bring that concern to the public view.”
Colquhoun said pilots want to see the WestJet Group consult all members on how to grow Swoop.
“They’ve done it unilaterally and they’ve done it in an environment where just recently we gave in major concessions to help them weather the storm,” he said.
“Our pilots have taken substantial cuts in wages and working conditions in order to help our airline through this pandemic. Right now, our guys are flying about a half to a third of what they were a year ago.”
The WestJet Group responded to the union’s concerns, telling Global News that Swoop is important to the company’s future.
“[Swoop] is well-positioned to serve price-sensitive travellers while stimulating demand in Canada’s largest market,” it said.
“After a drop in guest traffic of up to 95 per cent and with recovery slower than anticipated, stimulating demand in our industry is critical for our group’s survival. Toronto is our country’s largest air travel market, and every guest who flies with WestJet, Encore or Swoop is a win for our group, assisting in our recovery and supporting our collective future.”
The WestJet Group said its focus is “ensuring we have a long-term sustainable future” while “providing good jobs for thousands.”
There is no anticipated impact on WestJet operations.
© 2020 Global News, a division of Corus Entertainment Inc.
More than 100 People Gather for COVID-19 Protest in Windsor – AM800 (iHeartRadio)
The Great Demonstration Against Harmful COVID-19 Measures drew more than 100 people to downtown Windsor Sunday.
Protestors held signs rebelling against mask restrictions, quarantine protocols and what they’re calling “coerced testing” at the foot of Ouellette Avenue beneath The Great Canadian Flag for a rally around 1 p.m. — followed by a march up Ouellette Avenue where they stopped traffic in front of the Windsor-Essex County Health Unit on the corner of Erie Street.
Co-organizer Currie Soulliere, who launched a failed attempt to shop at Devonshire Mall without a mask earlier this summer, says protestors don’t want to see another lockdown.
“There’s always a threat that there may be another lockdown and we need a guarantee that there’s something protecting us from that happening again,” she says.
Medical Director of Health Dr. Wajid Ahmed previously said the protest is dangerous, potentially spreading the virus and information with no scientific backing.
That didn’t stop the crowd from chanting outside a likely unstaffed health unit on a Sunday afternoon.
“He didn’t want to speak to us, I’m pretty sure he said that, but we are going to make our presence known in front of the health unit,” Soulliere added.
Parts of Ottawa, Toronto, Peel and the York Region have seen modified Stage 2 restrictions imposed this month as hot spots in record case numbers in Ontario.
Windsor remains in Stage 3 of COVID-19 recovery and has few restrictions outside of phycical distancing rules and mask requirements.
Soulliere says protestors want a guarantee that won’t change.
“Some kind of guarantee that we’re not going to have any more lockdowns or shutdowns over what is amounting to a far less deadly virus than we were initially told, ” says Soulliere. “Honestly, a lot of us are questioning whether [Dr.] Wajid Ahmed should have his position at the health unit.”
There have been 42.5-million cases of COVID-19 documented globally since the pandemic began in April resulting in 1.15-million deaths, according to the World Health Organization.
Canada's transport regulator hasn't settled a single COVID-19 flight cancellation complaint – CBC.ca
Media Beat: October 26, 2020 | FYIMusicNews – FYI Music News
Kershaw shines against Rays to put Dodgers back on course toward World Series glory – CBC.ca
Silver investment demand jumped 12% in 2019
Iran anticipates renewed protests amid social media shutdown
Galaxy M31 July 2020 security update brings Glance, a content-driven lockscreen wallpaper service
- Media21 hours ago
COMMENTARY: How comics can teach media literacy and help identify fake news – Global News
- News19 hours ago
Coronavirus: What's happening in Canada and around the world on Sunday – CBC.ca
- News21 hours ago
How conspiracies like QAnon are slowly creeping into some Canadian churches – CBC.ca
- Sports17 hours ago
Khabib Nurmagomedov ends career with perfect record, perfect timing – MMA Fighting
- Media23 hours ago
How Donald Trump's Presidency Has Changed The Media – NPR
- Tech22 hours ago
A family that raised $2 million for their baby's life-saving medical treatment has received it for free – CNN
- Sports19 hours ago
Khabib Nurmagomedov's head coach reveals injuries, sickness star faced during UFC 254 training camp – MMA Fighting
- Investment17 hours ago
Buying Bitcoin ‘Like Investing In Google Early Or Steve Jobs And Apple,’ Predicts Wall Street Legend And Billionaire Paul Tudor Jones – Forbes